NTBL Notable Labs
- 0.446
- -0.004-0.84%
Notable Labs News
Notable Labs Analyst Ratings
JMP Securities Downgrades Notable Labs(NTBL.US) to Hold Rating
Notable Labs (NTBL) Was Downgraded to a Hold Rating at JMP Securities
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Notable Labs (NTBL)
Chardan Capital: Maintaining its rating at Notable Labs (NTBL.US), adjusted from buy to buy rating, and adjusted target price from $7.00 to $5.00.
Notable Labs Analyst Ratings
Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $5
Buy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP Platform
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)
Chardan Capital: Maintaining its rating at Notable Labs (NTBL.US), adjusted from buy to buy rating, and adjusted target price from $9.00 to $7.00.
Notable Labs Analyst Ratings
Buy Rating for Notable Labs: Financial Stability and Strategic Advances in AML Clinical Trials
Buy Rating Affirmed for Notable Labs on Strategic Clinical Advancements and Promising PPMP Platform
JMP Securities Maintains Market Outperform on Notable Labs, Lowers Price Target to $9
Notable Labs Analyst Ratings
Maintained Buy Rating on Notable Labs With Adjusted Price Target Amid Drug Setback and PPMP Platform Potential
Keay Nakae's Buy Rating on Notable Labs: Predictive Precision Medicine Platform and Financial Stability as Key Factors
Analysts Are Bullish on These Healthcare Stocks: Notable Labs (NTBL), Karuna Therapeutics (KRTX)
JMP Securities Initiates Coverage On Notable Labs With Market Outperform Rating, Announces Price Target of $13
Notable Labs Analyst Ratings
Analysis
Price Target
No Data
No Data